Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Ophthalmology Times® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the ophthalmic community.
ARVO 2024: A study on multi-ingredient oral supplement for dry eye symptoms and tear volume
May 7th 2024Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9, on a multi-ingredient oral supplement on dry eye symptoms and tear volume.
ARVO 2024: Post-hoc analysis of GOBI and MOJAVE trials for perfluorohexyloctane
May 7th 2024John Sheppard, MD, MSc, FACs, sat down to discuss post-hoc analysis of 2 FDA registration trials for perfluorohexyloctane, GOBI and MOJAVE, at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
ARVO 2024: Clinical evaluation of a novel lipid-containing eye drop
May 7th 2024Eric Donnenfeld, MD, sat down to discuss presentations on the novel new artificial tear, Blink Triple Care, about its efficacy in a non-controlled trial as well as comparison to the Classic Blink at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
ARVO 2024: Researchers detail novel glaucoma shunt
May 7th 2024In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.
ARVO 2024: Researchers drive innovation in retinal research
May 6th 2024A quartet of studies presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting addressed diverse retina-related challenges and unveiled findings with the potential to revolutionize vision science.
ARVO 2024: Vision-related activity difficulties in people diagnosed with nAMD and vision impairment
May 6th 2024Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.
ARVO 2024: Study validates ChatGPT 4.0 as potential uveitis patient resource
May 5th 2024In a presentation at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, researchers used Google’s recommended top 8 uveitis patient educational websites in the study to determine whether ChatGPT 4.0 could be used as a uveitis patient online resource.
ARVO 2024: Deep learning model for GA segmentation, adaptable to SS-OCT and SD-OCT data
May 5th 2024At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.
ARVO 2024: Understanding the reading problem for patients with central vision loss
May 5th 2024Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
ARVO 2024: Axial growth after discontinued soft multifocal contact lens wear, BLINK2 study
May 5th 2024David A Berntsen, OD, PhD, FAAO, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about axial growth after discontinuing soft multifocal contact lens wear in the BLINK2 study.
ARVO 2024: 36-month data from the GALE study of pegcetacoplan
May 5th 2024At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.
CIME 2024: Innovative approaches in glaucoma management center on the trabecular meshwork
May 5th 2024Deborah Ristvedt, DO, in her Controversies in Modern Eye Care presentation, discussed the evolution from traditional glaucoma treatments to novel therapies that target the trabecular meshwork and that aim to optimize IOP management without the need for multiple medications.
CIME 2024: Exploring the benefits of an interventional mindset in glaucoma treatment
May 5th 2024Inder Paul Singh, MD, highlights how early intervention, modern techniques, and reduced medication burden can improve outcomes and quality of life for patients with glaucoma in his presentation at the Controversies in Modern Eye Care conference.
CIME 2024: Diagnostic tips and treatments for managing Demodex blepharitis
May 4th 2024James A. Katz, MD, discussed evolving treatments for Demodex blepharitis, highlighting traditional methods like tea tree oil and microblepharoexfoliation as well as a newer FDA-approved therapy, and emphasizing the need to examine the upper eyelid carefully to diagnose the condition.